Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population‐based cohort study
Main finding · Ventricular arrhythmiaResult — go to the resultAdjusted hazard ratio 1.42 95% CI 1.18–1.69Authors' conclusion
Sulphonylureas are associated with an increased risk of VA when used as first-line therapy for type 2 diabetes relative to metformin use. This increased risk should be considered when prescribing sulphonylureas as an initial treatment for type 2 diabetes.
Study context
- Population
- Patients aged ≥18 years initiating pharmacotherapy for T2D, UK Clinical Practice Research Datalink Aurum, April 1998 to December 2019new users
- Participants
- 92,638 vs 506,882
- Exposure
- SU monotherapy vs metformin monotherapy
- Sulphonylurean = 92,638
- Metforminn = 506,882reference
- Outcome
- Ventricular arrhythmia (VA)
Methodological detailsactive comparator, new-user cohort design, inverse probability of treatment weighting by propensity score
- Active comparator, new-user cohort design
- Inverse probability of treatment weighting by propensity score
Main finding
Ventricular arrhythmia
Adjusted hazard ratio
1.42
95% CI 1.18–1.69
Events by group
Sulphonylureavs Metformin
aHR 1.42 (95% CI 1.18–1.69)
As reported in the abstract
Observational data: associations, not effects.
Original publication
Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population‐based cohort study. Diabetes Obes Metab. Published 16 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →